NGBiLab S3.E16: Cerebro Therapeutics episode artwork

EPISODE · Jun 30, 2026 · 31 MIN

NGBiLab S3.E16: Cerebro Therapeutics

from NGBideas · host Jim Wilson

Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's.Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether.In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University.Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients.Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.

Episode metadata supplied by the publisher feed · Published Jun 30, 2026

Embed this episode

Ready to play

NGBiLab S3.E16: Cerebro Therapeutics

0:00 31:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of NGBideas?

This episode is 31 minutes long.

When was this NGBideas episode published?

This episode was published on June 30, 2026.

Can I download this NGBideas episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!